The FDA Voted for 6 Peptides. Its Own Scientists Said No

Episode 410

0:00-1:06:20

An FDA advisory committee just voted to open a legal compounding supply line for six of seven peptides, including BPC-157 and TB-500, over the objection of the FDA's own scientists, who recommended against all seven. Dr. Jordan Feigenbaum walks through what the Pharmacy Compounding Advisory Committee actually voted on, why a vote about ulcerative colitis ends up governing tendon and joint use, what the single human BPC-157 trial does and doesn't show, and why "a pharmacy makes it safe" and "there's no money to study it" don't hold up. Evidence-based, no hype, no nocebo. Timestamps: | 00:00:00 | The FDA voted 8-6. What it actually means | 00:01:25 | What I am, and am not, claiming | 00:03:21 | How they got here: Category 2 and the paperwork | 00:07:17 | Who was in the room: the panel that flipped | 00:10:57 | What they voted on: compounding and the bulks list | 00:15:37 | "No money in it, you can't patent it" | 00:18:24 | The trials already run: Plevna and MK-677 | 00:22:55 | "I took it and it worked": placebo and fake surgery | 00:27:02 | The one human trial: Ruenzi 2005 | 00:32:28 | Is it natural? Is it even a drug? | 00:36:58 | Harm reduction, or follow the money?

Publisher

Barbell Medicine Podcast

Link

redcircle.com/shows/0cc66fc4-ccb8-4c60-8cc6-7367e52c4159/episodes/b789cdac-70dc-48e4-8caa-27636a97603a

Published

August 7, 2026

Duration

1h 6m

Format

Podcast

Category

Lifestyle · Health & Wellness

Source

RSS feed

Host

Barbell Medicine

BM

Barbell Medicine Podcast

@barbellmedicinepodcast

#fdavoted #peptides #ownscientists

The Nile